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In Mycobacterium tuberculosis, the carboxylation of acetyl coenzyme A (acetyl-CoA) to produce malonyl-CoA, a building block
in long-chain fatty acid biosynthesis, is catalyzed by two enzymes working sequentially: a biotin carboxylase (AccA) and a car-
boxyltransferase (AccD). While the exact roles of the three different biotin carboxylases (AccA1 to -3) and the six carboxyltrans-
ferases (AccD1 to -6) in M. tuberculosis are still not clear, AccD6 in complex with AccA3 can synthesize malonyl-CoA from
acetyl-CoA. A series of 10 herbicides that target plant acetyl-CoA carboxylases (ACC) were tested for inhibition of AccD6 and for
whole-cell activity against M. tuberculosis. From the tested herbicides, haloxyfop, an arylophenoxypropionate, showed in vitro
inhibition of M. tuberculosis AccD6, with a 50% inhibitory concentration (IC50) of 21.4 1M. Here, we report the crystal
structures of M. tuberculosis AccD6 in the apo form (3.0 Å) and in complex with haloxyfop-R (2.3 Å). The structure of M. tuber-
culosis AccD6 in complex with haloxyfop-R shows two molecules of the inhibitor bound on each AccD6 subunit. These results
indicate the potential for developing novel therapeutics for tuberculosis based on herbicides with low human toxicity.
Fatty acids are the precursors to manyMycobacterium tubercu-losis lipids, including mycolic acids, the -alkyl -hydroxy
branched long-chain fatty acids that are one of the main compo-
nents of the M. tuberculosis cell wall. The first committed and
rate-limiting step in fatty acid biosynthesis is the production of
malonyl coenzyme A (malonyl-CoA) from acetyl-CoA and bicar-
bonate by the acetyl-CoA carboxylase (ACC) (1). In M. tubercu-
losis, this biotin- and ATP-dependent reaction consists of two cat-
alytic steps. The first, biotin carboxylation, is catalyzed by the
-subunit, which contains both biotin carboxylase (BC) and bio-
tin carboxylate carrier protein (BCCP) in one polypeptide chain.
BC couples carbonate to a biotin residue covalently linked to the
BCCP domain to form carboxybiotin (2). The second step is the
carboxyl transfer from carboxybiotin to acetyl-CoA, catalyzed by
the -subunit, carboxyltransferase (CT) (Fig. 1).
Most bacteria, including Escherichia coli and Staphylococcus
aureus, have a multisubunit ACC composed of three functional
polypeptides: BC, BCCP, and CT (2), while in yeast and mam-
mals, ACC is a single polypeptide with distinct BC, BCCP, and CT
domains (3). The M. tuberculosis genome contains three genes
annotated as BC/BCCP -subunits (AccA1 to AccA3) and six CT
-subunits (AccD1 to AccD6) (4), which is unusual, since other
bacteria generally have only 1 or 2 ACCs (2). Presumably, the
multiple -subunits reflect the ability of mycobacteria to carbox-
ylate not only acetyl-CoAbut also several other distinct substrates,
including the short acyl chains that serve as intermediates in gly-
colipid biosynthesis (5, 6). Therefore, the presence of multiple
AccA and AccD genes within the M. tuberculosis genome is
thought to be linked to the wide variety of lipids found in M.
tuberculosis (4, 5, 7, 8).
OfM. tuberculosis’s 6 CT enzymes (AccD1 to -6), only AccD4,
AccD5, and AccD6 were shown to be essential for the mycobacte-
ria’s viability (6, 9, 10). Quantitative real-time PCR analysis has
demonstrated that the nonessential AccD1 to -3 do not show sig-
nificant changes in expression throughoutM. tuberculosis growth
phases, while AccD4 to -6 are expressed at higher levels during the
exponential growth phase (11). AccD4’s function in the cell is still
not known. AccD5 has been shown to be a propionyl-CoA car-
boxylase working with AccA3, to yield methylmalonyl-CoA as re-
action product, but it is also capable of using acetyl-CoA as the
substrate, with lower Km and Vmax (4, 12). AccD6 also has been
shown to form an active ACC holoenzyme with AccA3, using
acetyl-CoA as its substrate (11).
The amino acid sequence identities of AccD6 (EC 6.4.1.3;
Rv2247, gene accD6) with the other M. tuberculosis AccDs range
from 19% to 37% (27% for AccD1, 28% for AccD2, 19% for
AccD3, 32% for AccD4, and 37% for AccD5). M. tuberculosis
AccD6 has higher similarity to the acetyl-CoA carboxylase -sub-
unit (AccB) and propionyl-CoA carboxylase -subunit (PccB) of
Streptomyces coelicolor, with sequence identities of 38% and 41%,
respectively.
Herbicides as ACC inhibitors. Aryloxyphenoxypropionate
(FOP) and cyclohexanedione (DIM) are herbicides that target
plant ACCwith little human toxicity (13, 14). They have also been
found to have significant activity against apicomplexan parasites
that cause malaria (15) and toxoplasmosis (16). Growth inhibi-
tion of Toxoplasma gondii by FOP herbicides has been shown to
correlate with the inhibition of its ACCs (16). The study of FOP
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andDIM action on T. gondii (16), as well as on yeast gene replace-
ment strains (17), indicates that inhibition of ACCactivity leads to
a complete inhibition of the organisms’ growth, as in plants (18).
The effect of the herbicides haloxyfop and diclofop was previously
evaluated against M. tuberculosis AccA3-AccD6 and AccA3-
AccD5 holoenzymes at a 100 M concentration. Haloxyfop and
diclofop inhibit AccA3-AccD6 complex activity by 60 and 13%,
respectively (11). Diclofop was shown to inhibit AccA3-AccD5
acetyl-CoA carboxylation by 90% and propionyl-CoA carboxyla-
tion by only 30% (12). Earlier studies of the singleM. tuberculosis
AccD5 subunit demonstrated that its activity was not inhibited by
diclofop and haloxyfop (5).
Cocrystal structures for CT subunits bound to substrates have
been reported from a variety of species, but only the Saccharomy-
ces cerevisiaeCT domain crystal structure has been solved in com-
plex with the herbicides haloxyfop (19), tepraloxydim (20), and
pinoxaden (a phenylpyrazolin) (21), showing one molecule of
herbicide bound to the active site.
Here we present the first structure of M. tuberculosis AccD6.
We also characterize the ACC-inhibiting activity of the FOP her-
bicide haloxyfop against AccD6 and the crystal structure of M.
tuberculosisAccD6 in complex with haloxyfop, revealing two cop-
ies of the inhibitor bound to each subunit of the AccD6 ho-
modimer.
MATERIALS AND METHODS
Protein cloning, expression, and purification. A 1,422-bp DNA frag-
ment containing the AccD6 gene (Rv2247) was amplified by PCR using
M. tuberculosis H37Rv genomic DNA as a template (BEI Resources, Col-
orado State University). The following oligonucleotides were used as the
forward and reverse primers, respectively: 5=-AGATGAAGCCATATGAC
AATCATGGCCCCCGAGGCGGTTG-3= and 5=-AGAGTAAGCTTACA
GCGGGATGTTCTTGAGGCGGCC-3=. The amplified DNA fragment
was purified using the QIAquick PCR purification kit (Qiagen), following
the manufacturer’s protocol. The purified DNA fragment was digested
with NdeI and HindIII and then ligated using the corresponding restric-
tion sites into a pET-28b vector (Novagen) to yield an N-terminal 6His
tag recombinant vector. BL21 Star (DE3) cells were transformed with the
AccD6::pET-28b vector. An overnight culture was diluted to 1:50 in fresh
medium and grown to mid-log phase at 37°C in LB media (Difco). The
cells were induced with 1 mM (final concentration) IPTG and grown for
16 h at 16°C.
Cells were harvested by centrifugation. The cell pellet was resuspended
in 20 mM Tris-HCl (pH 7.5), 10 mM imidazole, 0.5 M NaCl, and 10%
glycerol (vol/vol) containing 1 mM DNase, 1 mM MgCl2, and Complete
EDTA-free protease inhibitor cocktail (Roche). The cell suspension was
lysed using a French press at 18,000 lb/in2, and the resulting cell lysate was
centrifuged at 15,000 g at 4°C for 1 h. The supernatantwas collected and
filtered through a 0.2-m filter and loaded onto a HisTrap nickel chelat-
ing column (GE Healthcare). His6-tagged AccD6 was eluted with a 0.2-
liter linear gradient of 75 to 500mMimidazole in 20mMTris (pH7.5), 0.5
M NaCl, and 10% glycerol (vol/vol). The eluted protein was dialyzed
overnight in a solution of 20 mM Tris (pH 7.5), 50 mM NaCl, 10% glyc-
erol (vol/vol), and 1 mM dithiothreitol (DTT). The purified protein was
concentrated to 14 mg ml1 prior to crystallization. Size exclusion chro-
matography confirmed that AccD6 is a two-subunit oligomer in solution
(data not shown).
M. tuberculosis AccD6 activity assay. AccD6 activity was monitored
by measuring the reverse reaction rate (Fig. 1). Using malonyl-CoA as a
substrate, the formation of acetyl-CoA was coupled to the citrate syn-
thase-malate dehydrogenase (CS/MDH) reaction involving the reduction
of NAD (22). The formation of NADH, which is proportional to the
activity ofM. tuberculosisAccD6,wasmeasured spectrophotometrically at
340 nm using a Thermo Scientific Multiscan Go plate reader. The MDH
reaction was initially kept in equilibrium in the absence of AccD6. Addi-
tion of AccD6 to the reaction mix, in the presence of CS, induces oxalac-
etate consumption by CS and shifts the equilibrium of theMDH reaction,
leading to the AccD6-dependent formation of NADH. The reaction,
which was carried out in a Corning 384-well plate at 30°C, wasmonitored
for 30 min. The 100 l reaction mixture contained 0.6 mgml1 BSA, 100
mMpotassium phosphate (pH 8.0), 20mM L-malic acid, 0.5 mMNAD,
6 mM biocytin, 3.6 U ml1 MDH, 6.8 U ml1 CS, and various concen-
trations of malonyl CoA (0 to 40 M). The kinetic parameters were cal-
culated at an enzyme concentration of 2 M and 1% (vol/vol) dimethyl
sulfoxide (DMSO). Data were fitted to the Henri-Michaelis-Menten
equation (HMM):
v Vmax[S] ⁄ Km [S] (1)
in which v,Vmax, [S], andKm correspond to, respectively, the steady-state
reaction rate, the maximum reaction rate, substrate concentration, and
the HMM constant for substrate S, using the GraphPad Prism demo ver-
sion for Windows (GraphPad Software, La Jolla, CA, USA).
M. tuberculosis AccD6 inhibition assay. Ten commercially available
herbicides, reported as ACC ligands (23), were selected for their evalua-
tion as possible M. tuberculosis ACC inhibitors. The compounds tested
were clodinafop, cyhalofop, haloxyfop, fluazifop, and diclofop (from the
FOP family) and sethoxydim, alloxydim, cycloxydim, tepraloxydim, and
tralkoxydim (from the DIM family). Their inhibitory activity against M.
tuberculosis whole cells was evaluated against MC2-7000 strain cultures
(10 ml Difco 7H9, 100 l dextrose, 1 ml oleic acid-albumin-dextrose-
catalase [OADC], 85 l NaCl [10% solution], 25 l Tween 80, 10 l of
malachite green [0.25 mg/ml], and 1 mM pantothenic acid), grown for 3
days, and diluted to an optical density at 600 nm (OD600) 0.005. Each
compound was tested in the 100 M to 100 nM range. After 6 days of
incubation at 37°C, culture plates were stained with resazurin and read on
the 7th day. The enzymatic inhibitory activity was assessed under the
conditions described in the “M. tuberculosis AccD6 activity assay” above,
in the presence of 300 M malonyl-CoA, and various concentrations of
FIG 1 The reaction catalyzed by ACC proceeds in two steps. The biotin carboxylase (BC) step involves the carboxylation of a biotin molecule bound to a biotin
carboxylase carrier protein (BCCP), followed by the transfer of the carboxyl moiety to an acetyl-CoA molecule, catalyzed by a carboxyltransferase (CT; M.
tuberculosis AccD6), forming the product malonyl-CoA.
Crystal Structure of Mycobacterium tuberculosis AccD6
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each compound (10 to 2,000 M), independently. The reaction mixtures
were incubated at room temperature for 20 min and were initiated by the
addition ofmalonyl-CoA. The dose response wasmeasured by calculating
the decrease in initial velocity, and 50% inhibitory concentrations (IC50s)
were assigned according to equation 2:
vi ⁄ vo 1 ⁄ [1 I] ⁄ IC50n] (2)
where vi/vo, [I], and n are enzyme fractional activity in the presence of
inhibitor I, inhibitor concentration, and the Hill coefficient, respectively.
Haloxyfop-R-methyl synthesis. Haloxyfop-R-methyl (methyl ester,
AK Scientific, Inc.) was hydrolyzed to the acid form. Haloxyfop-R-meth-
ylpropanoic acid (referred to here as haloxyfop-R), 2-[4-[[3-chloro-5-
(trifluoromethyl)-2-pyridinyl]oxy]phenoxy] methyl ester (2R) (0.24
mmol), was dissolved in 10 ml of 2:1:1 tetrahydrofuran-CH3OH-H2O
and then subjected to the addition of LiOHmonohydrate (3.0 equivalent,
0.72 mmol, 30.2 mg). The solution was stirred overnight and then ex-
tracted with three 6-ml portions of diethyl ether. The aqueous phase was
acidified to pH 1 with 2 M HCl (aq), and the resulting mixture was ex-
tracted with two 5-ml portions of ethyl acetate. The light yellow organics
were dried over anhydrousMgSO4 for 5min, filtered, and concentrated in
vacuo to afford the desired product as an analytically pure pale yellow
liquid (60 mg, 69% yield). 1H nuclear magnetic resonance (NMR) (500
MHz, CDCl3) data are as follows:  13.15 (s, 1), 8.55 (s, 1), 8.50 (s, 1), 7.16
(d, 2), 6.92 (d, 2); 4.85 (q, 1), 1.52 (d, 3), HPLC-MS: 98% at 254 nm, MS
m/z 360, 362 (M-H).
Isothermal titration calorimetry (ITC). An ITC200 microcalorim-
eter (MicroCal, Inc., Northampton, MA) was used to carry out ITC ex-
periments.M. tuberculosis AccD6 at 50 M and 2 mM haloxyfop-R in 20
mMTris-HCl (pH 7.5), 50mMNaCl were used to fill the sample cell (200
l) and syringe (39.7 l), respectively. The reference cell (200 l) con-
tained water. Thirty-six injections of ligand into macromolecule were
carried out at 30°C and 500 rpm. The first injection was 0.5 l, while the
remaining injections were 1 l each with 10-s durations and 5-min spac-
ing. The first data point (corresponding to the first ligand injection) was
not included in data analyses. Control titrations (ligand into buffer) were
performed to subtract the heat of dilution andmixing for each experiment
prior to data analysis. ITC data were fitted to equation 3:
GH TS RTlnKa (3)
where 	H is the enthalpy of binding, 	G is the Gibbs free energy change,
	S is the entropy change, T is the absolute temperature in kelvins, R is the
gas constant (1.987 cal K1 mol1), and Ka is the association constant.
The dissociation constant, Kd, was calculated as the inverse of Ka. Data
were evaluated using Origin 7 SR4 software (MicroCal, Inc.).
Crystallization, data collection, and refinement. Initial crystalliza-
tion screening ofM. tuberculosisAccD6was performed via the sitting drop
method using the Crystal Screen I and II, Index, SaltRx (Hampton Re-
search), and Wizard I and II (Emerald Biosciences) screening kits. Crys-
tals were grown by mixing 3 l of protein solution with 2 l of well
solution and equilibrated by hanging-drop vapor diffusion at 295 K in
24-well Linbro trays containing 500 l well solution. Crystals were ob-
tained in 5 to 7 days. Apo AccD6 was crystallized in 60% Tacsimate. The
apo crystals were flash-cooled with Paratone N (Hampton Research, La-
guna Niguel, CA), and the X-ray diffraction data were collected at the
Advanced Photon Source 23-ID beam line using a MAR 300 charge-cou-
pled device (CCD) detector (MarMosaic; Marresearch). HKL2000 (24)
was used to integrate and scale the diffraction data. Examination of the
diffraction data disclosed that the crystals were twinned in a pseudomero-
hedral manner, and the correct space group was P212121. The test for
pseudomerohedral twinning was accomplished using phenix.xtriage, and
phenix.refine was used to refine twinned data with a twin law of k,h,l.
Diffraction images also exhibited anisotropy and ellipsoidal truncation.
Anisotropic scaling was performed on the data prior to refinement (25).
The structure of apo AccD6 was solved by molecular replacement as
implemented in PHASER (University of Cambridge, United Kingdom)
(26). The complete PccB protein from S. coelicolor (PDB accession code
1XNV) (25) was used as a search model with water and ions removed.
For the formation of the AccD6 inhibitor complexes, haloxyfop-R
dissolved in DMSO as a 100 mM stock solution was added to the concen-
trated protein solution at a molar ratio of 5:1 and incubated for 1 h at
16°C. The haloxyfop-R complex was crystallized with 3.5 M sodium for-
mate. Crystals were transferred directly to a cryoprotectant (30% ethylene
glycol; HamptonResearch) and flash-cooled in a liquid nitrogen stream at
100 K before data collection.
AccD6-haloxyfop-R diffraction data were collected at the Advanced
Light Source Beamline 5.0.2 (Lawrence Berkeley National Laboratory,
Berkeley, CA) with a Quantum 315 charge-coupled device detector. The
HKL2000 program package was used for integration and scaling of the
haloxyfop-bound crystals. The AccD6 haloxyfop-R complex structure
was solved by molecular replacement using PHASER with chain A of the
apo AccD6 structure as a search model. All refinement was performed by
PHENIX (26) with intermittent manual model building done in COOT
(27). Refinement statistics are summarized in Table 1. Geometry of the
models was assessed withMOLPROBITY (28). All pictures were rendered
with PyMol (29).
Protein structure accession numbers. Structures were deposited in
the Protein Data Bank with the accession codes 4FB8 (for the apo struc-
ture) and 4G2R (for the haloxyfop-R bound structure).
RESULTS AND DISCUSSION
M. tuberculosis AccD6 activity and inhibition assays. M. tuber-
culosis AccD6 activity was measured in the coupled malate dehy-
drogenase and citrate synthase assay that follows the formation of
NADH at 340 nm (22). For the purified recombinantM. tubercu-
losis AccD6, the Km for malonyl-CoA was calculated to be 390

TABLE 1 Crystallographic statistics for the M. tuberculosis AccD6 apo
and haloxyfop-R complex structures
Parameter Apo Haloxyfop-R
Data collection
Space group P212121 I222
Resolution 50–3.0 63–2.3
Twin fraction 0.48 NA
Unit cell a, b, c (Å) 82.3 82.4 157.9 117.8 126.2 161.7
Redundancy 11.9 (8.7) 7.0 (6.3)
Observations 20,652 54,918
Observations test set 1,096 1,996
Completeness (%) 97.8 (90.4) 100 (99.0)
Rmerge 15.2 (88.1) 7.80 (3.90)
Rpim 0.02 (0.11) 0.01 (0.14)
I/I 29.5 (2.83) 12.9 (2.70)
Refinement
Rwork 23.7 16.6
Rfree 30.4 19.8
No. of atoms
Protein 6,221 6,483
Solvent 5 552
Ligand (including ions) 0 95
Ramachandran analysis
Most favorable allowed
(%)
95.9 99.8
Root mean square deviation
Bond lengths (Å) 0.008 0.007
Bond angles (°) 1.227 1.118
Reddy et al.
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70 M, and the Vmax was 5.5
 0.4 M min
1 (Fig. 2A). The M.
tuberculosis AccD6 Km for malonyl-CoA is higher than Km values
described for all other CTs studied to date; for example, E. coli and
yeast CTs haveKm values of 100M(30) and 75M(19), respec-
tively.
Of the 20 commercially available FOP and DIM herbicides
tested for their effect on M. tuberculosis AccD6 activity, only ha-
loxyfop (racemic mixture) showed inhibitory activity against
AccD6, with an IC50 of 70.2 
 1 M (Fig. 2B). It is known that
only the R enantiomer, haloxyfop-R, has herbicidal activity,
whereas the S enantiomer is essentially inactive (31). The haloxy-
fop-R enantiomer was synthesized and tested against AccD6, and
it yielded an IC50 of 21.4
 1.1M (Fig. 2C) against theM. tuber-
culosis enzyme. This shows that, like for plants, the R enantiomer
is the active species.
A previous study reported haloxyfop (racemic mixture) inhib-
iting AccA3-AccD6 complex activity (60% inhibition at a concen-
tration of 100 M) (11). Notwithstanding, diclofop also was re-
ported to inhibit the AccA3-AccD6 complex (13% inhibition at
100 M) (11), although we detected no inhibition of AccD6 at a
concentration of 100 M. Similar results have been reported for
AccD5 (5, 12). While AccA3-AccD5 was reported to be inhibited
by diclofop (90% and 30% inhibition at 100 M, using acetyl-
CoA and propionyl-CoA as the substrates) (12), AccD5 was not
inhibited in the presence of diclofop up to 300 M (5). This sug-
gests that the interactions of diclofop with AccD5 may be depen-
dent upon the formation of a carboxylase-carboxyltransferase
(AccA-AccD) complex. The same study reported that the M. tu-
berculosisAccD5 subunit is not inhibited by haloxyfop (5), despite
its similarity (37% identity) to M. tuberculosis AccD6. The same
set of herbicides showed no influence on growth when tested
againstM. tuberculosis whole cells.
Overall structure of M. tuberculosis AccD6. The crystal struc-
tures of apo and haloxyfop-bound M. tuberculosis AccD6 were
determined at 3.0-Å and 2.3-Å resolutions, respectively (Fig. 3A to
C). The atomic model of both the structures is in agreement with
the X-ray diffraction data and the expected value for geometric
parameters (Table 1). Unlike the hexameric ring-shaped architec-
ture found in the assembly ofM. tuberculosis AccD5 (5), AccD6 is
a homodimer resembling the yeast and E. coli ACC CT domains.
Each subunit of the homodimer is comprised of 473 amino acids.
Thirteen residues of the N terminus and 25 residues of the C
FIG2 M. tuberculosisAccD6 in vitro assays. (A) Reaction velocity plotted versusmalonyl-CoA concentration (Km 390
 70M;Vmax 5.5
 0.4Mmin
1).
(B) IC50 (70.2
 1 M) plot of racemic haloxyfop inhibition ofM. tuberculosis AccD6. (C) IC50 (21.4
 1 M) plot of haloxyfop-R inhibition ofM. tuberculosis
AccD6.
FIG 3 Ribbon diagram ofM. tuberculosis AccD6. (A) Ribbon diagram of the two subunit AccD6 holoenzyme, with the haloxyfop ligands depicted as sticks and
balls. Subunits are depicted by differences in color, both colored by secondary structure. Subunit 1 is in blue and subunit 2 is yellow. (B) Ribbon diagram (colored
by secondary structure) of the apo AccD6 single subunit. (C) Superimposition ofM. tuberculosis AccD6 subunit 1 (blue) and subunit 2 (tan). C RMSD, 1.0 Å.
Subunits are shown as ribbons.
Crystal Structure of Mycobacterium tuberculosis AccD6
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terminus in each subunit were not modeled due to disorder in
both structures. The protein has amixed/ foldwith a total of 17
-helices and 16 -strands that resemble the crotonase superfam-
ily fold (32, 33) (Fig. 3B). Each subunit of the dimer consists of two
domains: theN-terminal domain (-helices 1 to 7 and-strands 1
to 10) and the C-terminal domain (helices 8 to 17 and -strands
11 to 16). H4 and H5 of the N-terminal domain of one subunit
andH13 andH14 of the C-terminal domain of the second subunit
(Fig. 3A) form the dimer interface. Both subunits contain a
-sheet flanked on each side by -helices.
Comparison of M. tuberculosis AccD6 to other CT domains.
A subunit of the M. tuberculosis AccD6 (chain A, 435 residues
from Apo AccD6; PDB code 4FB8) was compared to both the
eukaryotic (human, PDB code 3FF6, and yeast, PDB code 1UYT)
and prokaryotic (E. coli, PDB code 2F9Y, and S. coelicolor, PDB
codes 1XNVand 3MFM)CTdomain structures usingCaspR (34).
Despite an overall sequence identity of about 20% between the
enzyme from M. tuberculosis and the eukaryotic CT domains, all
structures exhibit the same general fold. Superposition showed
that the M. tuberculosis AccD6 has root mean square differences
for C (C RMSD) of about 1.4 Å with the human CT domain
(chain A) (35) and 1.4 Åwith the yeast CT domain (chain A) (19).
M. tuberculosis AccD6 aligned with S. coelicolor PccB (41% se-
quence identity [36]) and AccB (38% sequence identity [37]),
showing C RMSD of 1.7 Å and 1.69 Å.
E. coli AccD is a heterodimer with an 22 subunit composi-
tion (38).M. tuberculosis AccD6 has C RMSD of 1.7 Å and 1.9 Å
in comparison to the E. coli N-terminal domain of the -subunit
and the -subunit C-terminal domain. In comparison to M. tu-
berculosisAccD6, theN terminus of theE. coliCTdomain contains
a 30-residue extension shown to be a zinc finger domain (38). The
zinc finger domain is proposed to act as a lid that closes upon
substrate binding in the active site (38) and has been detected in all
of the prokaryotic ACC enzymes studied to date. Similar to eu-
karyotic ACCs, M. tuberculosis AccD6 does not contain a zinc
finger motif.
M. tuberculosis AccD6 substrate binding pocket. Alignment
of the M. tuberculosis AccD6 structure with the previously re-
ported -subunit of ACC from S. coelicolor in complex with
acetyl-CoA (39) allowed us to model the binding and interactions
of acetyl-CoA and biotin with active site residues. The M. tuber-
culosisAccD6 active site is formed by the dimer interface, as shown
in Fig. 3A. This interface provides contacts that are essential for
substrate specificity, catalysis, and protein stability, being highly
conserved among biotin-dependent carboxyltransferases (36).
Both the acetyl-CoA binding pockets and the biotin pockets
are located at the interface between the N-domain of one mono-
mer and the C-domain of its dimeric partner. In S. coelicolorACC,
the key catalytic residue consists of two pairs of oxyanion-stabiliz-
ing residues (the oxyanion holes). Gly419 and Ala420 hydrogen
bond with the carbonyl group of biotin, whereas Gly182 and
Gly183 hydrogens bond with the carbonyl group of acetyl-CoA.
These four residues are highly conserved among the CT domains
of different species, including M. tuberculosis AccD6 (Gly336,
Ala367, Gly137, and Gly138) (Fig. 4A).
Given the high degree of sequence homology in the active site
ofM. tuberculosis AccD6 and those of other ACCs, it is very likely
that the substrate binding is highly conserved. The entrance to the
active site is an opening which measures approximately 8 Å by 14
Å on the surface and leads to a cavity of approximately 400Å3. The
cavity is defined by alpha helices H2, H5, and H14 as well as the
loop between 15 and H16 and expands to allow substrate bind-
ing. A model of the substrate in the active site indicates that the
adenine and phosphate moieties of the substrate are likely solvent
exposed, making contacts with polar residues from the surface of
the protein and the acyl portion of acetyl-CoA inserts into the
cavity of the protein. The adenine moiety lies next to the loop
preceding -strand 15 and the loop preceding H4= and H2= (the
prime designates the other subunit in the dimer). The adenine
NH2 extension is poised to hydrogen bond with the backbone
oxygen of Ala99, while the adenine N7 atom is in position to
hydrogen bond with Met64. The phosphate oxygen atoms of
acetyl-CoA are positioned to form electrostatic interactions with
Lys401, Lys403, and Lys404. The terminal carbonyl oxygen atom
FIG 4 M. tuberculosisAccD6 active site. (A) Two sets of oxyanion-stabilizing residues are highly conserved among the CT domains of different species, including
the NH of Gly137 and Gly138 and the NH of Gly336= and Ala367=. The structural similarity strongly suggests a similar enzyme mechanism. (B) Comparison of
theM. tuberculosis AccD6 and yeast ACC (PDB code 1OD2) active sites. The yeast structure is in blue, while theM. tuberculosis structure is in tan and biotin is
in tan. Side chains within 4 Å of each ligand are depicted as sticks.
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fits into an oxyanion hole composed of the backbone nitrogen
atomofGly131 and the nitrogen atomof the tetrahydrothiophene
ring of the biotin molecule. The biotin substrate lies deeper in the
cavity, next to the acyl-CoA chain, and is largely buried.
The active site organization is conserved in other CT domains,
such as that of S. aureus (38), as well as in the -subunit of ACC
from S. coelicolor (39) and S. cerevisiae (40) in complexwith acetyl-
CoA. The crystal structure of the yeast CT in complex with acetyl-
CoA shows the ligand binding site resides between the N-terminal
domain of one subunit and the C-terminal domain of another
subunit in the dimer interface (40). There areminor differences in
the N7 position of acetyl-CoA, which hydrogen bonds with
Lys1592 in the yeast structure, versus Met64 in theM. tuberculosis
structure. A significant difference is the charged residues that in-
teract with the phosphate groups of CoA: Lys403 and Lys404 side
chains in the M. tuberculosis AccD6 structure (Fig. 4B) and
Arg2036 and Arg2037 in the yeast CT structure.
M. tuberculosis AccD6 haloxyfop-R complex. The crystal
structure of AccD6 cocrystallized with a 3-fold molar excess of
haloxyfop-R shows twomolecules of inhibitor bound per subunit
of AccD6. Electron density for the bound inhibitor is shown in Fig.
5A. The structure of other ACC-inhibitor complexes describe the
binding of only onemolecule per subunit, and this is the first time
a second inhibitor binding site is observed bound to anACC. Both
haloxyfop-R binding sites are located at the subunit interface. The
first binding site (designated site 1) is located in a cleft that par-
tially overlaps with the active site (Fig. 5B). The second binding
site (site 2) is an adjacent pocket with no described function (Fig.
5C). The first site is connected to the second site by a small channel
approximately 6 Å in diameter and 5 Å in length.
Comparison of the haloxyfop-bound AccD6 to the apo form
shows that the main differences between the two structures are
located on the residues and secondary structural elements sur-
rounding both haloxyfop binding sites (superimposition of the
apo and haloxyfop bound structures reveals a CRMSDof 1.0 Å).
Haloxyfop binding site 1 is formed by three helices encompassing
H13, H14, andH5=. In site 1, the carboxyl end of haloxyfop is near
the protein surface, while the trifluoromethylpyridyl is buried
deeper to allowhydrophobic contacts. The trifluoromethylpyridyl
group is sandwiched between the aromatic side chains of Tyr141
and Tyr326. The phenyl ring in the center of haloxyfopmakes van
der Waals contacts with Gly366 and Gly137, while the trifluorom-
ethyl group makes hydrophobic interactions with Tyr326. In site 1,
the carboxylate group of haloxyfop forms hydrogen bonds with the
backbone amides of Gly138 (2.84 Å) and Ala99 (2.85 Å) (Fig. 6A).
The haloxyfop binding site 2 (Fig. 5C) is formed by the C-ter-
minal region of H13, H6=, the N-terminal loop of H6=, the C-ter-
minal loop to -strand 9, and H5=. This site is similar to site 1 in
that it contains a solvent-exposed carboxyl group and a trifluo-
romethylpyridyl ring that is buried deeper in the hydrophobic
environment of the protein. The trifluoromethylpyridyl ring
forms hydrophobic contacts with Val157. The phenyl ring in the
center of haloxyfop makes van der Waals and hydrophobic con-
tacts with Trp334, Val190, and Ser188. In site 2, haloxyfop makes
only one hydrogen bond: the carboxyl group to the backbone
amide of Trp334 (2.7 Å). The methyl group is positioned to make
hydrophobic contacts with His184 (Fig. 6B).
At site 1 (Fig. 5B), Tyr141 and Tyr326 rotate to accommodate
the stacking interactions with haloxyfop. The phenyl ring in the
center of haloxyfop in site 1 forcesH5 outward (approximately 1.5
Å) in comparisonwith the apo structure, while the carboxyl group
forces the loop between 6 and H4 (bearing residue Ala99) out-
ward by 1.1 Å. At haloxyfop binding site 2 (Fig. 5C), the haloxyfop
phenyl ring in the center displaces H6 by 2.1 Å. Both rings of the
haloxyfop in site 2 shift the loop between 9 and H5 (bearing
residue Val157) outward in comparison to the apo structure (by
approximately 1.3 Å). The trifluoromethyl group of haloxyfop at
site 2 is located near Met151, which adopts a different rotamer
conformation than in the apo structure; 9 also shifts approxi-
mately 1.3 Å.
Structural basis of M. tuberculosis AccD6 inhibition. Ha-
loxyfop occupies theM. tuberculosis AccD6 substrate binding site
FIG 5 (A) Electron density of haloxyfop (yellow sticks) and composite OMITmap electron density (blue contoured at 1 ). (B) Haloxyfop interaction withM.
tuberculosis AccD6 binding site 1; (C) haloxyfop interaction withM. tuberculosis AccD6 at binding site 2. Haloxyfop is in yellow, and protein side chains are in
green. Dashed lines represent hydrogen bonds, and numbers represent distances, in Å.
Crystal Structure of Mycobacterium tuberculosis AccD6
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and disrupts the oxyanion hole, where the haloxyfop central phe-
nyl ring would prevent Gly131 from interacting with the acyl
group. The haloxyfop carboxyl tail partially overlaps with the acyl
tail position of the CoA substrate, competing with it for binding.
Both the haloxyfop-bound structure and the apo structure have
two channels accessing the active site: one that leads from the side
closer to the CoA binding site and one that leads from the side
closer to the biotin binding site (Fig. 7A).Haloxyfop binding site 1
(Fig. 7B) obstructs the CoA binding channel, while binding site 2
(Fig. 7C) obstructs the channel leading to the biotin-accommo-
dating part of the pocket. Additionally, haloxyfop binding site 2 is
formed by a set of residues unique to M. tuberculosis AccD6 that
form a hydrophobic pocket: Trp334 (Asn1965 in yeast), His185
(Met1785 in yeast), His184 (Ile1782 in yeast), and Val338
(Leu1968 in yeast). Trp334 is perhaps themost essential residue in
forming binding site 2 because not only does it form a wall of the
pocket, but also its side chain packing allows the backbone to
hydrogen bond to haloxyfop. Thus, the two haloxyfop binding
sites may play a synergistic role in interfering with both substrate
binding and product dissociation, resulting in a more potent in-
hibition than the proteins containing single haloxyfop binding
sites seen in other species.
Isothermal titration calorimetry (ITC). The binding of the
two haloxyfop-R molecules to M. tuberculosis AccD6 was further
characterized by ITC measurements to determine the stoichiom-
etry of interaction (n) and the dissociation constant (Kd). The ITC
plot obtained from titration of haloxyfop-R is displayed in Fig. 8.
Data were best fitted to the single-mode data analysis, giving an n
FIG 6 Haloxyfop interactions with residues on binding site 1 (A) and binding site 2 (B). Hydrogen bonds are depicted as green dashed lines, and hydrophobic
interactions are depicted as red half circles.
FIG 7 (A) Haloxyfop-R entry points to binding sites 1 and 2. A surface representation of AccD6 (tan) and the relationship of site 1 (haloxyfop in yellow) with
site 2 (haloxyfop in cyan) is shown. Ligands are shown as sticks. (B and C) Comparison of the M. tuberculosis AccD6 and S. cerevisiae haloxyfop-binding sites.
Protein is shown as ribbons, with haloxyfop and selected side chains shown as sticks and colored by element. (B)Haloxyfop site 1 superimposition.M. tuberculosis
AccD6 is shown in purple, and the yeast CT domain is shown in green. (C) Haloxyfop site 2.M. tuberculosisAccD6 is in red, and the yeast CT domain is in green.
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value of 1.83
 0.03 and a molar ratio of 2:1. The n value is con-
sistent with the structural data of two molecules of haloxyfop-R
bound per subunit. The Kd value of 35.8 
 1.38 M is in agree-
ment with the IC50. These results are indicative of the presence of
two binding sites on each subunit; however, further experiments
are necessary to determine whether these sites have equal affinities
for haloxyfop-R and whether binding is cooperative. Besides the
differences in the set of amino acids that compose each binding
site, the interactions of haloxyfop at both binding sites 1 and 2 are
highly similar when theH-bonding pattern and number of hydro-
phobic contacts are compared. These features might help to ex-
plain the best fit of data to the single binding mode.
The thermodynamic discrimination profile for haloxyfop-R
binding (	H  9,300 cal/mol; T	S  3,122 cal/mol/degree;
	G6,177 cal/mol) indicates that its interaction with AccD6 is
mostly enthalpy driven (due to hydrogen bond donors’ and ac-
ceptors’ good placement on both binding sites [Fig. 6A and B] as
well as favorable van der Waals interactions) and presents unfa-
vorable entropy (due to haloxyfop-R flexibility and high polarity).
Compounds with favorable enthalpy of binding have been de-
scribed as good starting molecules for further drug development
through entropic optimization by the addition of more hydro-
phobic groups (41), which can lead to highly selective tight-bind-
ing inhibitors (42).
The presence of two binding sites for haloxyfop raises two
equally promising opportunities: (i) the development of high-af-
finity inhibitors capable of binding to both sites would likely re-
duce the emergence of resistance from single pointmutations, and
(ii) the spatial relationship of two binding sites allows the explo-
ration of the channel that connects them. The addition of substit-
uent groups that can interact with the amino acid side chains
positioned in the connecting channel can improve binding by
exploring less specific hydrophobic contacts. These features are
both related to inhibitors with a lower frequency ofmutations that
cause drug resistance (43).
M. tuberculosis AccD6 and AccD5 differences can explain
haloxyfop-R selective inhibition of AccD6. M. tuberculosis
AccD6 shares 37% sequence identity withM. tuberculosis AccD5,
with a 1.6-Å RMSD (C atoms). However, the oligomeric state of
M. tuberculosis AccD6 is dimeric, while M. tuberculosis AccD5 is
characterized as a hexamer in solution (8). As described above,M.
tuberculosis AccD5 has been characterized as a propionyl-CoA
carboxylase (12) and is not inhibited by haloxyfop (5). Compari-
son ofM. tuberculosisAccD6 andAccD5 reveals that the selectivity
is rooted in the portion of the haloxyfop binding cavity (site 1)
that is occupied by the terminal acid of haloxyfop in the AccD6
structure (Fig. 9A). Haloxyfop is likely to be sterically blocked
from binding to this region of AccD5, due to the larger side chain
of Tyr167, which is Val111 in AccD6. In addition, the comparison
of the structures of AccD6with haloxyfopwith apo-AccD5, shows
that residue His195 (Ala139 in AccD6) and Tyr128 (Gly72 in
AccD6) in AccD5 force Leu124 into the haloxyfop binding site,
while the corresponding residue in AccD6 (Met68) does not ex-
tend into the binding pocket, which hinders haloxyfop binding.
Ser163 of AccD5 also helps fill this portion of the haloxyfop site to
a larger degree than the equivalent residue inAccD6 (Ala107) (Fig.
9A). AccD4, the third essential AccD forM. tuberculosis survival, is
not inhibited by the FOP andDIMherbicides tested here (data not
shown).
Structural analysis of M. tuberculosis AccD6 and yeast CT
domain differential haloxyfop activity. Haloxyfop also binds to
the yeast CT domain but displays much weaker in vitro inhibition
activity (IC50 of500Mfor the yeast CT domain [40]). In order
to uncover possible structural explanations for differences in in-
hibition, we further compared the binding mode of haloxyfop to
M. tuberculosis AccD6 site 1 with that of the yeast CT domain
(PDB code 1UYS) (19).
In both structures, the pyridyl ring is engaged in - stacking
interactions with aromatic amino acids. However, the nature of
the stacking rings is different (Fig. 7B and 9B). Tyr326, which
stacks with the pyridyl ring, is a phenylalanine residue in the cor-
responding position of the yeast structure. The side chain oxygen
atom of this tyrosine residue allows a larger degree of stabilization
by means of a water-mediated hydrogen bond to the backbone
nitrogen of Thr160 (2.9 Å from the tyrosine side chain oxygen
atom to the water and 2.6 Å from the water to the backbone ni-
trogen of Thr160). InM. tuberculosis AccD6, the stacking interac-
tions of Tyr326, the pyridyl ring, and Tyr141 form a more ideal
interaction than the same stacking interactions in the yeast struc-
ture, where the pyridyl ring is tilted approximately 45° out of the
plane formed by both aromatic side chains. The oxygen atom on
the side chain of Tyr326 (compared to Phe1956 in the yeast struc-
ture) creates a more compact packing area around the ligand,
which may be why it is 1.0 Å farther from this aromatic group in
theM. tuberculosis AccD6 structure. Phe115 in theM. tuberculosis
AccD6 structure is an alanine residue (Ala1712) in the corre-
sponding position of the yeast CT domain. Consequently, Phe115
is positioned in such a way that Tyr141 is approximately 2 Å closer
to haloxyfop, which allows a tighter stacking interaction in theM.
tuberculosis site.
The haloxyfop trifluoromethyl group interactions differ be-
tween the two organisms (Fig. 9C). The M. tuberculosis AccD6
FIG 8 ITC curve of binding of haloxyfop-R to M. tuberculosis AccD6.
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trifluoromethyl group is surrounded by the side chains of the res-
idues Tyr326, Ala370, Gly341, Val337, and Leu295, whereas the
trifluoromethyl group in the yeast CT domain is packed around
the side chains of Val1967, Trp1924, Val2002, Ile1974, and
Gly1971. The most striking difference between the two structures
in reference to the trifluoromethyl packing is the presence of the
Trp1924 side chain in yeast and Leu295 in the corresponding po-
sition of M. tuberculosis AccD6. Not only does the indole side
chain providemore packing surface area and a different electronic
environment, it is also involved in a stacking interaction with an-
other tryptophan residue side chain (Trp1953; Val323 in M. tu-
berculosis AccD6). Finally, the terminal acid group of haloxyfop is
within hydrogen bonding distance of two atoms in the M. tuber-
culosis AccD6 structure (2.9 Å to the Gly138 backbone nitrogen
atom and 2.5 Å to the Ala99 backbone nitrogen atom), whereas
the yeast CT domain has a longer hydrogen bond (3.1 Å to
Ala1627 backbone nitrogen atom) (Fig. 9D).
Conclusion. M. tuberculosis AccD6 is an attractive drug target
because of its vital role in fatty acid biosynthesis (44). The results
presented here demonstrate that haloxyfop is an inhibitor of M.
tuberculosis AccD6. The AccD6-haloxyfop bound structure re-
veals a second binding site for the inhibitor on each subunit of the
AccD6 dimer. The atomic structure of the enzyme-inhibitor com-
plex provides detailed information of the binding mode for the
further development of higher affinity inhibitors. Furthermore,
the proximity of both binding sites in each subunit, and the iden-
tification of a communicating channel, opens the possibility for
experiments exploring these binding sites for improvements in
both affinity and residency time of lead compounds.
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